Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Mechanism mediated by a noncoding RNA, nc886, in the cytotoxicity of a DNA-reactive compound

(2019) Nawapol Kunkeaw et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

New therapeutic strategies to treat human cancers expressing mutant p53 proteins

(2018) Giovanni Blandino et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overexpressing TPTE2 (TPIP), a homolog of the human tumor suppressor gene PTEN, rescues the abnormal phenotype of the PTEN–/– mutant

(2018) Daniel F. Lusche et al.   Oncotarget

Expression of Insulin-Like Growth Factor Binding Protein-5 (IGFBP5) Reverses Cisplatin-Resistance in Esophageal Carcinoma

(2018) Dessy Chan et al.   Cells

Lung cancer: current therapies and new targeted treatments

(2017) Fred R Hirsch et al.   LANCET

Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity

(2017) Lihui Wang et al.   Cell Death & Disease

YEATS2 links histone acetylation to tumorigenesis of non-small cell lung cancer

(2017) Wenyi Mi et al.   Nature Communications

Epigenetic silencing of serine protease HTRA1 drives polyploidy

(2016) Nina Schmidt et al.   BMC CANCER

New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy

(2016) Francesco Gentile et al.   JOURNAL OF MOLECULAR GRAPHICS & MODELLING

Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms

(2016) L Wang et al.   Cell Death & Disease

Anti-tumor activity of SL4 against breast cancer cells: induction of G2/M arrest through modulation of the MAPK-dependent p21 signaling pathway

(2016) Li-Hui Wang et al.   Scientific Reports

Targeting the invasive phenotype of cisplatin-resistant Non-Small Cell Lung Cancer cells by a novel histone deacetylase inhibitor

(2015) Valentina Zuco et al.   BIOCHEMICAL PHARMACOLOGY

Overexpression of stathmin is resistant to paclitaxel treatment in patients with non-small cell lung cancer

(2015) Ruifang Sun et al.   TUMOR BIOLOGY

Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach

(2015) Lihui Wang et al.   Oncotarget

Cisplatin in cancer therapy: Molecular mechanisms of action

(2014) Shaloam Dasari et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Silencing XIAP suppresses osteosarcoma cell growth, and enhances the sensitivity of osteosarcoma cells to doxorubicin and cisplatin

(2014) YANG QU et al.   ONCOLOGY REPORTS

Alpha-1-Antitrypsin: A Novel Human High Temperature Requirement Protease A1 (HTRA1) Substrate in Human Placental Tissue

(2014) Violette Frochaux et al.   PLoS One

Systems biology of cisplatin resistance: past, present and future

(2014) L Galluzzi et al.   Cell Death & Disease

HtrA Protease Family as Therapeutic Targets

(2013) Joanna Skorko-Glonek et al.   CURRENT PHARMACEUTICAL DESIGN

HtrA1 Downregulation Induces Cisplatin Resistance in Lung Adenocarcinoma by Promoting Cancer Stem Cell-Like Properties

(2013) Yongqing Xu et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Role of the Copper Transporter, CTR1, in Platinum-Induced Ototoxicity

(2013) S. S. More et al.   JOURNAL OF NEUROSCIENCE

Pre-Clinical Studies of Epigenetic Therapies Targeting Histone Modifiers in Lung Cancer

(2013) Kenneth Huffman et al.   Frontiers in Oncology

Down-Regulation of HtrA1 Activates the Epithelial-Mesenchymal Transition and ATM DNA Damage Response Pathways

(2012) Ning Wang et al.   PLoS One

Sensitization of tumor cells by targeting histone deacetylases

(2011) Paola Perego et al.   BIOCHEMICAL PHARMACOLOGY

The retinoid X receptors and their ligands

(2011) Marcia I. Dawson et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

HtrA1 sensitizes ovarian cancer cells to cisplatin-induced cytotoxicity by targeting XIAP for degradation

(2011) Xiaoping He et al.   INTERNATIONAL JOURNAL OF CANCER

Molecular mechanisms of cisplatin resistance

(2011) L Galluzzi et al.   ONCOGENE

The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer

(2011) Kenneth J. O’Byrne et al.   Cancers

HtrA proteins as targets in therapy of cancer and other diseases

(2010) Dorota Zurawa-Janicka et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

The Serine Protease HtrA1 Specifically Interacts and Degrades the Tuberous Sclerosis Complex 2 Protein

(2010) M. Campioni et al.   MOLECULAR CANCER RESEARCH

Anoikis resistance and tumor metastasis

(2008) Craig D. Simpson et al.   CANCER LETTERS

HDAC family: What are the cancer relevant targets?

(2008) Olaf Witt et al.   CANCER LETTERS